文献速递前列腺增生与排尿功能障碍男科与性医学

血清睾酮与双氢睾酮和下尿路症状的发生与进展:REDUCE研究结果

Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study.
PubMed 文献 · J Urol · 2023-10-24

REDUCE研究的事后分析纳入3009例无症状男性和2145例有症状男性,评估基线血清睾酮与双氢睾酮五分位与下尿路症状发生及进展的关联。结果显示,无症状男性中血清睾酮或双氢睾酮与下尿路症状发生无关(P=.9,P=.4),有症状男性中与下尿路症状进展无关(P=.9,P=.7),安慰剂组与度他雄胺组结果相似(交互作用P均≥.3)。

要点

  • 无症状男性中,血清睾酮或双氢睾酮与下尿路症状发生无关(P=.9,P=.4)。
  • 有症状男性中,血清睾酮或双氢睾酮与下尿路症状进展无关(P=.9,P=.7)。
  • 安慰剂组与度他雄胺组结果相似,交互作用P均≥.3。

核心结论

  • 在REDUCE研究中,较高的血清睾酮和较高的血清双氢睾酮与无症状男性的下尿路症状发生或有症状男性的下尿路症状进展均无关。
  • 这些数据不支持中年男性血清雄激素与下尿路症状相关的假说。

研究设计与样本

  • REDUCE研究的事后分析,纳入3009例无症状男性和2145例有症状男性。
  • REDUCE是一项随机试验,在前列腺特异性抗原升高且研究前活检阴性的男性中评估度他雄胺预防前列腺癌的作用。
  • 使用Cox模型估计多变量校正风险比和95%置信区间,检验基线血清睾酮和双氢睾酮五分位与下尿路症状发生及进展的关联,并按治疗组(度他雄胺 vs 安慰剂)检验交互作用。

主要发现

  • 无症状男性中,无证据表明血清睾酮或双氢睾酮与下尿路症状发生相关(P=.9,P=.4)。
  • 有症状男性中,无证据表明血清睾酮或双氢睾酮与下尿路症状进展相关(P=.9,P=.7)。
  • 安慰剂组和度他雄胺组结果相似(交互作用P均≥.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Though the pathogenesis of benign prostatic hyperplasia is unclear, it was previously believed that increasing androgen levels contributed, though not all data support this idea. We tested if elevated serum testosterone or dihydrotestosterone were risk factors for lower urinary tract symptoms incidence in asymptomatic men and for lower urinary tract symptoms progression in symptomatic men. MATERIALS AND METHODS: A post hoc analysis of REDUCE was performed in 3009 asymptomatic men and in 2145 symptomatic men. REDUCE was a randomized trial of dutasteride for prostate cancer prevention in men with an elevated prostate-specific antigen and negative prestudy biopsy. We estimated multivariable adjusted hazard ratios and 95% confidence intervals using Cox models to test the association between quintiles of serum testosterone and dihydrotestosterone at baseline and lower urinary tract symptoms incidence and progression and tested for interaction by treatment arm (dutasteride vs placebo). RESULTS: In asymptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms incidence (P = .9, P = .4). In symptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms progression (P = .9, P = .7). Results were similar in both placebo and dutasteride arms (all P interaction ≥ .3). CONCLUSIONS: In REDUCE, higher serum testosterone and higher serum dihydrotestosterone were not associated with either lower urinary tract symptoms incidence in asymptomatic men or lower urinary tract symptoms progression in symptomatic men. These data do not support the hypothesis that serum androgens in middle-aged men are associated with lower urinary tract symptoms.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Daniels JP, Mirocha J, Adjei M, et al. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study. J Urol. 2023. PMID: 37873943. doi:10.1097/JU.0000000000003738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。